• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senseonics wins coverage from Aetna for Eversense glucose monitor

October 23, 2018 By Sarah Faulkner

Senseonics - updated logoSenseonics (NYSE:SENS) said this week that won coverage from health plan provider Aetna for its Eversense continuous glucose monitoring system.

Aetna provides coverage for roughly 22 million people in the U.S., according to Senseonics, making it the third largest commercial health plan provider in the country.

“We are pleased that one of the largest national payers in the U.S. is now covering Eversense, and that Aetna recognizes the value of CGM and the value Eversense can bring to the market in terms of patient adherence,” Tim Goodnow, president & CEO of Senseonics, said in prepared remarks. “We believe this coverage decision represents a major milestone and has the potential to facilitate broad patient and physician access to Eversense in the U.S.”

The company’s 90-day, implantable Eversense system, which won FDA approval in June, includes a small sensor that is implanted just below the skin in an outpatient procedure. It continuously measures glucose levels, sending that data to a mobile app every five minutes and alerting users if their glucose levels drop out of range.

Senseonics launched the Eversense system in August and touted that it won coverage for the CGM with Horizon Blue Cross Blue Shield of New Jersey and Horizon Healthcare of New Jersey.

SENS shares were trading at $3.64 apiece in pre-market activity today, up +5.2%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Featured, Patient Monitoring, Wall Street Beat Tagged With: Senseonics

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS